B
Beijing Huahao Zhongtian Biopharmaceutical
Innovative oncology treatments targeting breast cancer brain metastasis with advanced pharmaceutical R&D
About Beijing Huahao Zhongtian Biopharmaceutical
Biostar Pharma is a biopharmaceutical company specializing in the development of innovative oncology treatments, particularly for breast cancer brain metastasis. The company operates in the pharmaceutical industry, focusing on research and development (R&D) to create advanced therapeutic solutions. Biostar Pharma's core product, Utidelone Injection UTD1, has received FDA clearance for a Phase 2 study and has shown promising results, including a 73% CNS ORR (Central Nervous System Overall Response Rate) and a 100% CBR (Clinical Benefit Rate). The company serves healthcare providers, hospitals, and clinics that treat cancer patients, particularly those with complex metastatic conditions. Biostar Pharma's business model revolves around the development, clinical testing, and eventual commercialization of its pharmaceutical products. Revenue is generated through the sale of these specialized treatments, as well as potential partnerships and licensing agreements with other pharmaceutical companies.
Source: Dealroom company dataNews
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| IPOOther financing | Oct 2024 | $24M | $705M | Undisclosed | ↗ |
| SERIES EOther financing | Nov 2020 | $135M | $540M | CCB International · Tianjin Venture Capital · Chengdu Bio-Town Investment · Matrix Partners China | — |
Growth signals
Latest recorded traffic for Beijing Huahao Zhongtian Biopharmaceutical is 350 monthly website visits, down 75% over the last three months. Beijing Huahao Zhongtian Biopharmaceutical's team grew 0% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Beijing Huahao Zhongtian Biopharmaceutical in the Dongcheng District ecosystem
The Beijing Huahao Zhongtian Biopharmaceutical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later7 investors entered at this stage
Detong Capital
Matrix Partners China
CCB International
Tianjin Venture Capital- CIChengdu Bio-Town Investment
CICC- ECEfung Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Beijing Huahao Zhongtian Biopharmaceutical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Beijing Huahao Zhongtian Biopharmaceutical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










